Abiopharma

🔍 Lee Kevin (Executive)

Company: BICYCLE THERAPEUTICS PLC (BCYC)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 165,000 shares of Ordinary Shares (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 640,310.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 10,325 shares of Ordinary Shares at $6.8 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 629,985.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 10,989 shares of Ordinary Shares at $6.46 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 618,996.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Acquired 330,000 shares of Employee Stock Option (right to buy) at $7.08 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: 0 | shares_owned_after: 330,000.00 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: Represents a restricted share unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
• F2: Each RSU represents a contingent right to receive one ordinary share.
• F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5).
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.70 inclusive.
• F6: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares in 36 equal monthly installments thereafter.